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Traveler’s diarrhea is the most common health prob-
lem of international travelers. We determined the preva-
lence of Aeromonas spp. associated with traveler’s diar-
rhea and analyzed the geographic distribution, clinical fea-
tures, and antimicrobial susceptibility. Aeromonas spp.
were isolated as a cause of traveler’s diarrhea in 18 (2%)
of 863 patients. A. veronii biotype sobria was isolated in
nine patients, A. caviae in seven patients, and A. jandaei
and  A. hydrophila in one patient each. Aeromonas spp.
were isolated with a similar prevalence in Africa, Latin
America, and Asia. Watery and persistent diarrhea, fever,
and abdominal cramps were common complaints. All
strains were resistant to ampicillin; showed variable resist-
ance to chloramphenicol, tetracycline, and cotrimoxazole;
and were susceptible to cefotaxime, ciprofloxacin, and
nalidixic acid. The persistence of symptoms made antimi-
crobial treatment necessary.
T
raveler’s diarrhea is the main infectious disease report-
ed in persons traveling abroad. Among the microor-
ganisms responsible, bacteria represent approximately
61% (1). Enterotoxigenic Escherichia coli, enteroaggrega-
tive E. coli, and Shigella spp. are the most common bacte-
ria involved (1,2). Other bacteria that cause diarrhea, such
as Salmonella, Campylobacter, Yersinia, Aeromonas, and
Plesiomonas spp., are isolated less often (1).
The genus Aeromonas has high diversity: at least 16
DNA hybridization groups are recognized (3). Among
these genospecies, A. hydrophila, A. caviae, and A. veronii
biotype sobria are considered of clinical significance (4,5).
The spectrum of infectious diseases caused by Aeromonas
species includes gastrointestinal infections as well as
extraintestinal infections such as cellulitis, wound infec-
tions, septicemia, urinary tract infections, and hepatobil-
iary and ear infections, among others (6). Although healthy
carriers of Aeromonas spp. have been described, several
case-control studies have shown that these bacteria cause
diarrhea (6). With the incorporation of genotypic tech-
niques, identification of Aeromonas to species level has
improved (7). The main objective of this study was to
determine the prevalence of Aeromonas spp. as a cause of
traveler’s diarrhea and to analyze the species’ geographic
distribution, clinical features, and susceptibility to antimi-
crobial agents.
Methods
Patients
A total of 863 patients with traveler’s diarrhea were
recruited from the Tropical Medicine Unit of the Hospital
Clinic of Barcelona, Spain, during the period January
1999–December 2001. All patients completed an epidemi-
ologic questionnaire; their clinical history was taken, and a
physical examination was performed. Traveler’s diarrhea
was defined as the occurrence of three or more episodes of
watery stool within a 24-hour period, with or without other
symptoms, or the occurrence of unformed stools accompa-
nied by one of the following: vomiting, nausea, abdominal
cramps, fever, chills, prostration, or tenesmus. Persistent
diarrhea was defined as that of >14 days’ duration.
Microbiologic Tests
A stool sample was collected, sent to the Laboratory of
Clinical Microbiology, and processed for bacterial, viral,
and parasitologic studies. To isolate Aeromonas spp.,
blood agar supplemented with ampicillin and a selective
media, CIN (cefsulodin-irgasan-novobiocin) agar, were
used. After incubation at 37°C for 24–48 hours, an oxidase
test was performed on the colonies compatible with bacil-
li. Biochemical criteria were used to identify Aeromonas.
Identification of the species was performed by 16S
rDNA–restriction fragment length polymorphism as previ-
ously described (7,8). The biotype of A. veronii strains was
identified on the basis of a positive reaction to arginine
dihydrolase and negative response to bilis-esculin hydrol-
ysis and production of ornithine decarboxylase (9).
Susceptibility Testing
Antimicrobial susceptibility tests were performed by
using an agar disk diffusion method advocated by the
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(10). Antimicrobial disks (ampicillin 10 µg; cefotaxime 30
µg; chloramphenicol 30 µg; ciprofloxacin 5 µg; nalidixic
acid 30 µg; tetracycline 30 µg; and trimethoprim-sul-
famethoxazole 1.25/23.75 µg) were obtained from Becton
Dickinson (Cockeysville, MD). E. coli ATCC 25922 and
Pseudomonas aeruginosaATCC 27853 were used as qual-
ity-control strains.
Results
Distribution and Geographic Origin of Species
Causing Traveler’s Diarrhea
Aeromonas spp. were isolated as a cause of traveler’s
diarrhea in 18 (2%) of 863 patients. A. veronii biotype
sobria was isolated in nine patients, A. caviae in seven
patients, and A. jandaei and A. hydrophila in one patient
each (Table 1). In three of these patients, another
enteropathogen was also found: in one patient who had
traveled to Mexico, Shigella sonnei was isolated together
with  A. veronii; in another patient traveling to India,
Giardia lamblia was detected together with A. veronii;i n
the third patient, who had traveled to Thailand, Salmonella
Typhimurium was found with A. veronii. The frequency of
Aeromonas spp. as a cause of traveler’s diarrhea was sim-
ilar in patients returning from Africa (1.7%), Latin
America (1.8%), and Asia (2.3%) (Table 1).
Clinical Features
The signs and symptoms of Aeromonas  enteritis in
these 18 patients are summarized in Table 2. Sixteen of the
18 patients had watery diarrhea; these were the cases asso-
ciated with A. veronii biotype sobria and A. caviae. The
patients with enteritis caused by A. hydrophila and A. jan-
daei had loose stools. Fifty percent of the patients had
fever and abdominal cramps, whereas nausea and vomiting
were uncommon complaints. Gross blood was observed in
the stools of one patient, but this could be attributed to the
S. sonnei isolated in the same stool. In 9 of the 18 patients,
diarrhea was persistent. 
Antimicrobial Susceptibility
The antimicrobial susceptibility of Aeromonas spp. iso-
lates causing traveler’s diarrhea is shown in Table 3. All
strains were resistant to ampicillin but susceptible to cefo-
taxime, ciprofloxacin, and nalidixic acid. The susceptibili-
ty to chloramphenicol, tetracycline, and trimethoprim-sul-
famethoxazole varied. Some 66.6% of A. veronii biotype
sobria strains and 71.4% of A. caviae strains were suscep-
tible to chloramphenicol; 55.6% of A. veronii biotype
sobria strains and 71.4% of the A. caviae strains were sus-
ceptible to tetracycline; and 77.8% of A. veronii biotype
sobria and 100% of A. caviae were susceptible to trimetho-
prim-sulfamethoxazole.
Treatment
While travelling, two patients received treatment,
amoxicillin in one case and amoxicillin plus clavulanic
acid in the other. Patients with persistent diarrhea were
treated with the following antibiotics: norfloxacin (one
patient), ciprofloxacin (six patients), and trimethoprim-
sulfamethoxazole (two patients); all recovered.
Discussion
In this study we describe the prevalence of different
types of Aeromonas species associated with traveler’s diar-
rhea in a cohort of travelers to a variety of tropical and sub-
tropical countries. In contrast, other published studies have
often been selective in terms of the types of travelers, geo-
graphic areas visited, or attempts to isolate specific
microorganisms with the aim of testing antibiotic efficien-
cy. In our study, Aeromonas spp. were isolated in 18 (2%)
of 863 patients with traveler’s diarrhea. A. veronii biotype
sobria and A. caviae were the most frequently isolated
species. These findings agree with the results of Hänninen
et al. (11), who reported that these were the most common
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Table 1. Species and geographic distribution of clinical isolates of Aeromonas spp. causing traveler’s diarrhea 
Geographic area  A. veronii biotype sobria (n=9)  A. caviae (n=7)  A. jandaei ( n=1)  A. hydrophila (n=1) 
Guatemala  1  1     
India  2  1
a  1
a  1 
Iran    1     
Kenya  1       
Mali/Burkina Faso  1       
Mexico  2
b       
Nicaragua    1     
Paraguay    1     
Sahara  1       
Senegal    2     
Thailand  1       
aThis patient traveled to India and Nepal. 
bOne traveler also visited Guatemala. Aeromonas spp. associated with traveler’s diarrhea in
tourists traveling to Morocco. Likewise, Yamada et al. (12)
found that A. veronii biotype sobria was the Aeromonas
species most frequently implicated as a cause of traveler’s
diarrhea in Japanese travelers returning from unindustrial-
ized countries. In our study, the geographic distribution of
Aeromonas species did not favor any predominant area:
species were isolated with a similar prevalence in Africa,
Latin America, and Asia. However, all four species (A.
veronii biotype sobria, A. caviae, A. jandaei, and  A.
hydrophila) were isolated from patients returning from
India. In India, Aeromonas spp. has been identified as an
enteric pathogen in 1.8% of patients with diarrhea (13). In
a recent study performed in Dhaka (Bangladesh),
Aeromonas spp. were significantly associated with diar-
rhea, similar to occurrences in other countries (14–17).
In our study, 3 (16.7%) of the Aeromonas isolates were
detected together with other enteropathogens. This situa-
tion allowed us to consider that the symptoms we observed
in the patients with traveler’s diarrhea associated with
Aeromonas spp. were due to the presence of this
Aeromonas organisms. In our study, watery stools, fever,
and abdominal cramps were the most common symptoms,
which is consistent with other reports (11,18). Albert et al.
(18) suggested that isolates of Aeromonas spp. positive for
both the alt and  ast genes, which encode enterotoxins,
were associated with watery diarrhea but that isolates pos-
itive only for the alt gene were associated with loose
stools.
Fifty percent of the patients with Aeromonas spp.
enteritis had persistent diarrhea. Chronic diarrhea lasting
more than 1 year caused by A. caviae has been reported
(2). Adirect link between drinking water and food contam-
inated with Aeromonas spp. and gastrointestinal disease
has been demonstrated (19).
Patients with prolonged enteritis required treatment. A
quinolone was the drug of choice, although increased
occurrence of quinolone-resistant Aeromonas spp. strains
has been reported in industrialized countries (20,21).
Regarding the ß-lactam antibiotics, Aeromonas spp. strains
analyzed in this study were, as expected, uniformly resist-
ant to ampicillin, whereas third-generation cephalosporins,
such as cefotaxime, showed good activity. These results
are in accordance with those reported by other authors,
showing that third-generation cephalosporins are active
against Aeromonas spp. (2,22). The percentage of strains
with resistance to chloramphenicol, tetracycline, or
trimethoprim-sulfamethoxazole ranged from 22.9% to
45%. These levels of resistance are likely related to the
extensive use of these antimicrobial agents in unindustrial-
ized countries.
In summary, A. veronii biotype sobria and A. caviae are
the  Aeromonas species most frequently associated with
traveler’s diarrhea; watery diarrhea, fever, and abdominal
cramps are the predominant clinical features. The persist-
ence of symptoms makes the use of antimicrobial treat-
ment necessary.
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Table 2. Clinical features of patients with traveler’s diarrhea 
associated with Aeromonas spp. 
 
No. of patients with symptoms/ 
total patients (n=18) 
Sign or symptom 
A. veronii 
biotype sobria 
A. 
caviae  Overall
a 
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Persistent diarrhea  3/9  5/7  9/18 
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bIn this patient, a Shigella sonnei strain was also isolated. 
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